Drug Updates

Empowering Pharmaceutical Companies in Chronic Disease Research and Identifying Unmet Needs says Disease Landscape Insights

Chronic diseases are long term ailments that progress over time. They are non-communicable in nature and can lead to severe health complications if left undetected and untreated. Chronic disease prevalence has been increasing dramatically across the globe. Unhealthy lifestyle choices, rise in the geriatric populace, environmental degradation, genetic issues, and inadequate access to quality healthcare […]

Drug Updates

WuXi Vaccines Launches Its First Vaccines CDMO Site in China

WuXi Vaccines, a leading contract development and manufacturing organization (CDMO) focused on vaccine discovery, development, and manufacturing, has launched its first standalone vaccines CDMO site in Suzhou, China. The opening will add drug substance and drug product capacity, with end-to-end services for diversified vaccines that will accelerate global clients’ project timelines – from process development […]

MilliporeSigma Integrated mRNA Services
Drug Updates

MilliporeSigma to Become First Provider to Offer Fully Integrated mRNA Services

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, is the first CTDMO (contract testing, development and manufacturing organization) to offer integrated services for all critical stages of mRNA development, manufacturing, and commercialization, including products and testing. The company today opened two new GMP-grade mRNA drug substance manufacturing sites in Darmstadt […]

Drug Updates

RedHill Biopharma Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that on September 19, 2023, it received a letter from the Listings Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the thirty consecutive business days from August 7, 2023, to September 18, 2023, the bid price […]

HANSIZHUANG Approval for ESCC Treatment
Drug Updates

Henlius’ Novel Anti-PD-1 mAb HANSIZHUANG (Serplulimab) Approved for the Treatment of ESCC

Shanghai Henlius Biotech, Inc. (2696. HK) announced that the new drug application (NDA) for new indication of HANSIZHUANG (serplulimab injection), an innovative anti-PD-1 monoclonal antibody independently developed by the company, in combination with drugs containing fluorouracil and platinum for the first-line treatment of patients with PD-L1 positive unresectable locally advanced/recurrent or metastatic esophageal squamous cell […]

LEQEMBI Alzheimer's Treatment
Drug Updates

‘LEQEMBI® Intravenous Infusion’ approved for the treatment of Alzheimer’s disease in Japan

BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that “LEQEMBI® Intravenous Infusion” (200 mg, 500mg, lecanemab) has been approved in Japan as a treatment for slowing progression of mild cognitive impairment (MCI) and mild dementia due to Alzheimer’s disease (AD). The regulatory approval in Japan announced today, entitles BioArctic to a milestone […]

Drug Updates

Pierre Fabre Laboratories and Vernalis announce a drug discovery collaboration in oncology

Pierre Fabre Laboratories and Vernalis (R&D) Ltd (“Vernalis”), a fully owned subsidiary of HitGen Inc., are pleased to announce a long-term partnership to identify pre-clinical candidates against multiple oncology targets. Under the terms of the agreement, Vernalis will use its expertise to enable drug discovery against an undisclosed portfolio of targets and use fragment and […]

Drug Updates

Kexing Biopharm 2023 Innovation Forum on Targeted Drug Delivery

On September 15, “Kexing Biopharm 2023 Innovation Forum on Targeted Drug Delivery” successfully kicked off. This marks the first time in recent years that the Company has organized an event specifically focused on pharmaceutical R&D innovation. The forum focused on LNP- and extracellular vesicle-based drug delivery systems covering topics such as development trend, clinical research, […]

Drug Updates

Via Nova Therapeutics Announces FDA clearance of Investigational New Drug (IND) application for VNT-101, a novel direct-acting antiviral against Influenza A virus

Via Nova Therapeutics, Inc., a biotechnology company focused on discovering and developing therapeutics to treat viral infections with significant unmet medical need, today announced the clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) for its Influenza A nucleoprotein inhibitor, VNT-101. “We look forward to evaluating VNT-101 in […]

AI in Drug Discovery Illustration
Drug Updates

Unlocking the Future of Drug Discovery with Artificial Intelligence

BCC’s newly released report, titled “Global Artificial Intelligence in Drug Discovery Market,” unveils the extraordinary impact of artificial intelligence (AI) on the pharmaceutical and biotech sectors. Authored by Ms. Surbhi Jagtap, Senior Analyst, this study provides invaluable insights into the AI-driven revolution in drug discovery. BOSTON, Sept. 22, 2023 /PRNewswire/ — The report highlights a […]